AZENTA INC (AZTA)
Health Care · Life Sciences Tools & Services · NASDAQ
Azenta provides critical sample management and automated cold storage solutions that underpin life sciences research and clinical development.
What AZENTA INC does
Azenta, Inc. provides life science sample exploration and management solutions to the life sciences and healthcare industries. The company offers automated cold chain storage, sample management, and related analytical and genomic services. Its solutions are designed to support biological research, clinical trials, and clinical laboratory workflows.
Themes: life sciences research tools, biobanking and sample management, clinical trials support, cold chain logistics, genomics infrastructure
Fundamentals
- Price$36.76 as of 2026-10-21 close
- Market cap$1.6B as of 2026-08-03 (share count; price 2026-10-21)
- 1-year return+15.6% 2025-10-21 close $31.81 → 2026-10-21 close $36.76
- P/En/a negative earnings
- Net margin-9.4% FY2025, SEC XBRL
- Gross margin+45.5% FY2025, SEC XBRL
- ROE-3.3% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Revenue growth (YoY)+3.5% FY2025, SEC XBRL
- Revenue CAGR (3y)+2.2% SEC XBRL
- Beta1.38 as of 2026-09-03
- Last reported earnings2026-08-04 SEC EDGAR Form 8-K (Item 2.02)
Dividend: 1-year non-decreasing per-share dividend streak (SEC XBRL).
How AZTA compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- gross marginmiddle range 189 covered Health Care peers, as of 2026-09-03
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Dividend coverage
Not assessed — last reported dividend predates the accounts. The most recent fiscal year in which AZTA reported a dividend payment is FY2022, while its reported financial statements run through FY2025. Coverage is therefore not assessed for the latest year — an FY2022 ratio would not describe AZTA today.
Coverage is derived from reported SEC EDGAR XBRL figures, comparing dividends paid against net income and free cash flow for the SAME fiscal year. It is not shown here because the latest fiscal year with a reported dividend payment (FY2022) is older than the latest year of reported financial statements (FY2025), so any ratio would describe an out-of-date year. Informational only — not financial advice.
Quarterly results
| Quarter | Revenue | Gross profit | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|---|
| Q3 FY2026 2026-06-30 | $161M | $72M | -$4M | $2M | $0.05 | $1M† | $7M† |
| Q2 FY2026 2026-03-31 | $145M | $62M | -$166M | -$161M | -$3.49 | $14M† | $7M† |
| Q1 FY2026 2025-12-31 | $149M | $64M | -$7M | -$15M | -$0.34 | $21M | $6M |
| Q4 FY2025 2025-09-30 | $159M | $72M | $2M | $51M | $1.11 | $2M† | $8M† |
| Q3 FY2025 2025-06-30 | $144M | $66M | -$2M | -$48M | -$1.05 | $26M† | $11M† |
| Q2 FY2025 2025-03-31 | $143M | $63M | -$18M | -$48M | -$1.04 | $14M† | $7M† |
| Q1 FY2025 2024-12-31 | $147M | $69M | -$9M | -$11M | -$0.25 | $30M | $8M |
| Q4 FY2024 2024-09-30 | $151M | $68M | -$5M | -$7M | -$0.14 | $18M† | $9M† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$190M
- Short-term investments$136M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How AZENTA INC looks technically
AZENTA INC (AZTA) is trading 28.1% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 40 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 29, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 54, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 5 trading days ago (its momentum flipped negative). It made a new 20-day high about 13 trading days ago. It is 20.8% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 28.1% above its 200-day average, the long-term trend line — a longer-term uptrend | +28.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $34.36 | $34.36 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $28.70 | $28.70 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 15 calendar days ago — the swings before that are what the structure reading is measured on | 15 sessions |
| Wave structure | its recent swings can be read as a completed five-part upward sequence — the pattern Elliott-wave chartists call an impulse — which on that reading would now be due a pullback rather than more of the same; the labelling fails if price closes above 46.41. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible five-wave upward sequence, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 40 trading days ago — a "golden cross", a bullish long-term signal | 40 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 29, with buyers in control | 28.6 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 54, neither overbought (above 70) nor oversold (below 30) | 54.3 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($33.03 to $46.41) — its "stochastic" reading is 28 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 27.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 5 trading days ago (its momentum flipped negative) | 5 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $46.41 | $46.41 |
|---|---|---|
| From the 52-week high | it is 20.8% below its 52-week high (its highest price of the past year) | -20.8% |
| Above the 52-week low | it is 130.8% above its 52-week low (its lowest price of the past year) | +130.8% |
| Below the 52-week high | it is 20.8% below its highest point of the past year | 20.8% |
| Since a 20-day breakout | it made a new 20-day high about 13 trading days ago | 13 sessions |
| Since a 55-day breakout | it made a new 55-day high about 13 trading days ago | 13 sessions |
| All-time high | its highest closing price on record is $124.79 (set on 2021-11-09) | $124.79 |
| Given back of the 52-week move | over the past year its closes ranged ($16.02 to $42.73), and it has given back roughly a quarter of its rise from last year’s low — 22% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $25.37 to $26.22. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 22.4% |
| From the all-time high | it is 70.5% below its all-time high | -70.5% |
| Nearest price level | it is trading 4.0% above a support level at $35.28 — a price it turned at three times since 2025-03-18, most recently on 2025-07-24. Since 2024-10-21 it has 11 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -4.0% |
| All-time low | its lowest closing price on record is $2.52 (set on 2008-11-21) | $2.52 |
| Above the all-time low | it is 1358.7% above its all-time low | +1,359% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 44th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.18 between its high and its low — about 5.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.18 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $32.01 and $40.73 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $32.01 – $36.37 – $40.73 |
| Typical daily range (% of price) | its price moves about 5.9% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.9% |
| Stretch from the 200-day average | it is trading 3.7 daily ranges above its 200-day average price (28.1% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.7 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.56× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 5.4% since the prior reading | +5.4% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 6 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 6 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-10-21 0.8% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.8% |
|---|---|---|
| Open gap | it gapped 2.6% below the previous close 10 sessions ago and has not traded back through the level it left behind at 39.35 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -2.6% |
| Gap filled | a 2.4% gap up opened on 2026-10-06 has been "filled" 11 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 11 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 3 sessions in a row, a +7.83% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 3 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 9.0 percentage points (the stock gained 8.9% while the market lost 0.1%) | +9.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 34.9 percentage points (the stock gained 38.2% while the market gained 3.3%) | +34.9% |
| vs market, 6 months | over the past 6 months this stock beat the market by 30.1 percentage points (the stock gained 39.9% while the market gained 9.8%) | +30.1% |
| vs market, 12 months | over the past 12 months this stock beat the market by 0.4 percentage points (the stock gained 15.6% while the market gained 15.2%) | +0.4% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a strong uptrend, with buyers in control, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: MACD momentum is negative — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 13% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-15 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 4.8% of the share price. | +12.6% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 32% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $27.77 — a volume-weighted average of daily closes over 196 sessions, not a true tick-by-tick VWAP. | +32.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is 6% above the average price paid since it last reported on 2026-08-04 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $34.77 — a volume-weighted average of daily closes over 56 sessions, not a true tick-by-tick VWAP. | +5.7% |
Price levels it has turned at before
AZTA last closed at $36.76 on 2026-10-21. Since 2024-10-21 it has turned at 11 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $35.28 | Support | 4.0% below the last close | turned there three times · 2025-03-18 to 2025-07-24 |
| $38.45 | Resistance | 4.6% above the last close | turned there four times · 2024-11-18 to 2025-12-10 |
| $34.09 | Support | 7.3% below the last close | turned there twice · 2025-12-02 to 2025-12-17 |
| $32.98 | Support | 10.3% below the last close | turned there four times · 2025-10-03 to 2026-01-02 |
| $43.95 | Resistance | 19.6% above the last close | turned there twice · 2024-12-17 to 2025-02-18 |
| $47.55 | Resistance | 29.4% above the last close | turned there twice · 2024-11-29 to 2025-02-26 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $46.41.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 7 trading days, since 2026-10-13.
Read from daily closes as of 2026-10-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Trading above the 50-day moving average · Pulled back from the 12-month high · MACD just crossed bearish (12/26/9) · in a strong, established uptrend (ADX) · Analyst price target recently RAISED | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.17 mean, 1=Strong Buy…5=Strong Sell) — 4 analysts
- Mean price target$39.00 range $33.00 – $44.00; median $39.50
Analyst estimates, as of 2026-10-20. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for AZTA
- Consensus EPS estimate$0.116 next reporting period, as of 2026-10-20
- Estimate change, 30 days-$0.054 (-31.8%) from $0.17, on 2026-09-15, 35-day window
- Readings revised upward0% of 7 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["reliance on acquisitions to drive growth and potential integration challenges","risks associated with business transformation initiatives and cost-saving plans","sensitivity to fluctuations in research and development spending by customers"]
What changed in the latest 10-Q
AI-assisted comparison of AZTA's 10-Q filed 2026-08-06 against the prior one filed 2026-05-08.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (filed 2026-08-06) states the B Medical Systems sale was completed on July 1, 2026 for $63.0 million, consisting of $28.0 million cash paid prior to closing and $35.0 million funded through a Vendor Loan Agreement.
- Newer filing adds references to 'Part II, Item 1A "Risk Factors" in the Quarterly Report on Form 10-Q for the quarter ended March 31, 2026' in the forward-looking statements disclosure.
- Newer filing states the B Medical Systems business is excluded from MD&A as 'discontinued operations' rather than 'our B Medical Systems business'.
- Newer filing includes additional text: 'This major hub' at the end of the provided excerpt.
- Removed:
- Older filing (filed 2026-05-08) described the B Medical Systems sale as not yet closed as of March 31, 2026, with Thelema having deposited $9.0 million and expected to pay the remaining $54.0 million by March 31, 2026, and Thelema's financing not yet secured.
- Older filing stated 'approximately 83 countries' for sales, which is removed in the newer filing.
- Reworded:
- The newer filing changes references from 'three and six months ended March 31, 2026 and 2025' to 'three and nine months ended June 30, 2026 and 2025' throughout the MD&A organization and revision disclosure, reflecting the different quarter covered.
- Newer filing changes 'three and six months ended March 31, 2025' to 'three and nine months ended June 30, 2025' in the revision disclosure paragraph.
- Newer filing changes 'approximately 83 countries' to 'approximately 75 countries' and the employment date reference from 'as of March 31, 2026' to 'as of June 30, 2026'.
- Newer filing changes 'we employ approximately 2,900... as of March 31, 2026' to 'we employ approximately 2,900... as of June 30, 2026'.
- Newer filing changes 'the Share Purchase Agreement with Thelema S.À R.L. or Thelema' to 'a Share Purchase Agreement with Thelema S.À.R.L., or Thelema'.
- Newer filing changes 'definitive Sale and Purchase Agreement, or the Share Purchase Agreement' to 'a Share Purchase Agreement'.
- Newer filing changes 'which the Company estimated the fair value to be $2.5 million as of the measurement date' to 'which we estimated the fair value to be $2.5 million as of the acquisition date'.
- Newer filing changes 'excludes the operations of our B Medical Systems business' to 'excludes the operations of discontinued operations'.
- Newer filing changes 'core Sample Management Solutions and Multiomics segments' to 'core Sample Management Solutions, or SMS, and Multiomics segments'.
- Notes:
- The provided newer filing excerpt appears to be truncated at the end ('This major hub'), so changes after that point could not be assessed.
- Only the portions of MD&A included in the prompt could be compared; other sections of MD&A were not provided.
Risk Factors
- Added:
- Newer filing (2026-08-06) adds a risk factor titled 'We are exposed to credit risk under the $35.0 million secured vendor loan extended in connection with the divestiture of our B Medical Systems business, and we may not be repaid on a timely basis or at all.'
- Newer filing (2026-08-06) discloses that Azenta Germany GmbH extended a $35.0 million secured term loan to Thelema S.à r.l. in connection with the July 1, 2026 sale of the B Medical Systems business.
- Newer filing (2026-08-06) states the loan bears interest at 6.0% per annum and matures three months following the July 1, 2026 funding date.
- Newer filing (2026-08-06) states the loan represents a substantial portion of the $63.0 million purchase price.
- Newer filing (2026-08-06) states the buyer's obligations are secured by a first-priority pledge over 100% of the equity interests of B Medical Systems S.à r.l.
- Newer filing (2026-08-06) states the buyer is majority owned by an officer of the Company and that the loan and related arrangements were reviewed and approved through related-party transaction procedures.
- Removed:
- Older filing (2026-05-08) contains a risk factor titled 'Our business could be adversely affected if Thelema S.À R.L. fails to secure financing necessary to complete its acquisition of the B Medical Systems business,' which is not present in the newer filing.
- Older filing (2026-05-08) states that completion of the sale was conditioned upon the acquirer securing final residual financing for the remaining acquisition payment of $54.0 million on or before March 31, 2026.
- Older filing (2026-05-08) states that on March 27, 2026, the company was informed by Thelema that it had not yet secured the financing and the transaction did not close by March 31, 2026.
- Older filing (2026-05-08) states that either party may terminate the Share Purchase Agreement and the company will retain $5.0 million from the $9.0 million deposit as a break-up fee.
- Older filing (2026-05-08) contains a risk factor titled 'Our goodwill and intangible assets may become impaired,' which is not present in the newer filing.
- Older filing (2026-05-08) discloses goodwill of $553.1 million and net intangible assets of $91.4 million as of March 31, 2026.
- Older filing (2026-05-08) discloses non-cash impairment charges of $36.6 million for SMS and $112.4 million for Multiomics as of March 31, 2026.
- Reworded:
- Newer filing (2026-08-06) changes the introductory risk factor language to reference the Quarterly Report on Form 10-Q for the quarters ended December 31, 2025 and March 31, 2026, while the older filing (2026-05-08) references only the quarter ended December 31, 2025 filed on February 5, 2026.
- Newer filing (2026-08-06) states there have been 'no material changes' from the risk factors disclosed except for 'the additional risk factor' under 'Risk Related to Reliance on Third Parties,' while the older filing (2026-05-08) states there have been 'no material changes' except 'for the changes to the risk factor set forth below.'
- Notes:
- The newer filing text includes Items 2, 5, 6 and signature lines beyond the Risk Factors section; these were compared only where they formed part of the provided excerpts. Exhibit lists in Item 6 differ substantially between filings but are outside the Risk Factors section and were not compared in detail.
- The older filing excerpt appears truncated at the end (ends with 'First Amendment to Offer Letter, dated April 6, 2').
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
1 open-market purchase and 0 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 6 days since 2026-10-16 have not been checked yet.
- Last 90 days · read to 2026-10-161 buy ($8096) · 0 sells — 1 buying insider
- Last 180 days · read to 2026-10-162 buys ($171896) · 0 sells — 2 buying insiders
Activity heuristic: net buying (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-31. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about AZTA's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 4 matched disclosures for AZTA from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Institutional ownership (13F)
4 institutional 13F filers reported holding AZTA as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 10,847,556
- Reported value $276,829,040
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 0 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about AZTA's institutional holders → See what each manager we track holds →
Short interest (FINRA)
AZTA had 5,319,092 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
AZTA had 12.1% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 6.12 days to cover at the same settlement.
- Reported short interest (shares) 5,319,092
- Short interest (% of shares outstanding) 12.1%
- Prior settlement (shares) 5,382,386
- Reported change -1.18%
- Days to cover (reported) 6.12
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Thermo Fisher Scientific (TMO)
- Danaher (DHR)
- Brooks Automation (BRKS)
- Agilent Technologies (A)
- Revvity (RVTY)
- Bio-Techne (TECH)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare AZTA vs…
AZENTA INC is found in…
Frequently asked questions
What does AZENTA INC (AZTA) do?
Azenta, Inc. provides life science sample exploration and management solutions to the life sciences and healthcare industries. The company offers automated cold chain storage, sample management, and related analytical and genomic services. Its solutions are designed to support biological research, clinical trials, and clinical laboratory workflows.
What sector is AZENTA INC (AZTA) in?
AZENTA INC (AZTA) is classified in the Health Care sector. Its industry is Life Sciences Tools & Services. It trades on NASDAQ.
Does AZTA pay a dividend?
No — AZENTA INC (AZTA) does not currently pay a dividend (market data, as of 2026-09-03). Informational only — not financial advice.
Who are AZENTA INC's (AZTA) competitors?
Notable peers of AZENTA INC (AZTA) include Thermo Fisher Scientific, Danaher, Brooks Automation, Agilent Technologies and Revvity. This peer set is informational only — not financial advice.
Has there been recent U.S. House stock trading in AZTA?
Yes — we hold 4 matched STOCK Act disclosures for AZTA from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is AZENTA INC (AZTA) overbought or oversold right now?
AZENTA INC (AZTA) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 54, in the neutral middle (as of 2026-10-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on AZTA come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.